ReviewFrontiers in immunology2018
Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 49 citations in OpenAlex.
- Cord Blood Platelet-Poor Plasma Functionalizes Polycaprolactone Scaffolds for Coupled Vascularization and Osteogenesis in Bone Tissue Engineering.Tissue engineering and regenerative medicine · 2026Article
- Epigenetic reprogramming by BCG (Bacillus Calmette-Guérin) vaccination: A novel strategy to reverse immunodeficiency in chronic kidney disease.The Indian journal of medical research · 2026Review
- Computational design and molecular characterization of a multi-epitope peptide vaccine targeting pancreatic cancer.Journal, genetic engineering & biotechnology · 2026Article
- Prediction of SARS-CoV-2 exposure through T cell activation profiles.Scientific reports · 2026Article
- Mixed Lymphocyte Reaction: Functional Immune Profiling in Transplantation and Beyond.Diagnostics (Basel, Switzerland) · 2026Review
- Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next.NPJ vaccines · 2026Review
- MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment.Frontiers in immunology · 2026Review
- Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy.Journal of biomedical science · 2025Review
- Cancer vaccines as enablers of immunotherapy.Nature immunology · 2025Review
- The chronologic history of post-mastectomy breast reconstructive surgery in the United Kingdom from 1975 to 2025.Gland surgery · 2025Review
- The Interplay Between lncRNAs-microRNAs Network Dysregulation and Cellular Hallmarks of Thyroid Cancer.Cancers · 2025Review
- Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies.Journal of experimental & clinical cancer research : CR · 2025Review
- Functions and mechanisms of lncRNAs in immune escape and their application in immunotherapy for colorectal cancer.Journal of translational medicine · 2025Review
- Review
- Plant-derived recombinant macromolecular PAP-IgG Fc as a novel prostate cancer vaccine candidate eliciting robust immune responses.Transgenic research · 2025Article
- Harnessing immunotherapy: cancer vaccines as novel therapeutic strategies for brain tumor.Frontiers in immunology · 2025Review
- Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy.Frontiers in immunology · 2025Review
- Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment.Bioactive materials · 2024Review
- Chemoproteomics reveals immunogenic and tumor-associated cell surface substrates of ectokinase CK2α.Cell chemical biology · 2024Article
- Dendritic cell-targeted delivery of antigens using extracellular vesicles for anti-cancer immunotherapy.Cell proliferation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is great interest in developing efficient therapeutic cancer vaccines, as this type of therapy allows targeted killing of tumor cells as well as long-lasting immune protection. High levels of tumor-infiltrating CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.